New pill targets Hard-to-Treat cancers with specific gene flaw
NCT ID NCT07407504
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called GenSci145 in people whose advanced solid tumors have a specific change in the PIK3CA gene. The trial has two parts: first, finding a safe dose, then seeing if the drug works alone or with other treatments. About 186 adults aged 18-75 with tumors that have worsened after standard therapy are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GenSci145 tablets
- What this could lead to
- If successful, this could point toward a new targeted treatment option for people with advanced solid tumors that have a specific PIK3CA mutation.
- What could go wrong
- This is an early Phase 1/2 trial with only 186 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Cancer Hospital of the Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China